CSRxP on Lilly & Biogen Earnings

CSRxP released the following statement following the release of Eli Lilly and Biogen’s Q2 earnings today:

“Out-of-control prescription drug prices are fueling profits for brand-name drug companies like Eli Lilly and Biogen. Both companies announced higher-than-expected profits today, serving as an important reminder that the problem continues to be the price.  While the Administration’s Blueprint is a step in the right direction, today’s earnings announcements show that there is much work yet to be done by Congress and the Administration to implement lasting reforms that will lower prescription drug prices.”